Business
Indian pharma CDMO firms post strong Q2 growth amid global outsourcing shift
Reported by Aditya Chauhan (Staff Writer) · Livemint - Markets ·

Global drug companies are outsourcing more research and manufacturing to cut costs and diversify supply chains, making Indian contract development and manufacturing organisations major beneficiaries. While overall pharma earnings stayed mixed in the September 2026 quarter, select CDMO stocks delivered strong revenue growth in Q2FY27.
Blue Jet Healthcare Growth
Blue Jet Healthcare saw massive gains driven by a turnaround in its Pharma Intermediates and API vertical, which grew 322 percent year-on-year and 52 percent quarter-on-quarter as customer inventory destocking ended. Its Contrast Media Intermediates segment advanced 80 percent year-on-year and 25 percent quarter-on-quarter. The company developed amino acid derivatives for peptide fragments at its Hyderabad research center, and its Mahad Unit 3 backward integration project is nearing completion with a total capital deployed of 2,500 million rupees to go live in the second half of fiscal 2027. Pre-construction work is also ready for a 100-acre site in Vizag with commercial production from Phase 1 slated between late fiscal 2029 and 2030.
Acutaas Chemicals Expansion
At Acutaas Chemicals, advanced pharmaceutical intermediates revenue rose 53.1 percent year-on-year to 4,020 million rupees, supported by a scaling CDMO platform and over 25 percent volume growth in core generic intermediates. Meanwhile, speciality chemicals revenue fell 20 percent year-on-year to 349 million rupees due to a planned shift away from lower-margin commodities and a temporary shipment pause at Baba Fine Chemicals. Acutaas commercialised its third electrolyte additive, budgeted 3,000 million rupees in fiscal 2027 capital expenditure, and projects full-year revenue growth of about 30 percent with EBITDA margins between 38 and 40 percent.
Context
Contract development and manufacturing organisations handle outsourced drug research and production for major pharmaceutical companies across the world. India has grown into a leading hub for this work due to strong technical expertise and cost advantages.
More in Business
BusinessSource: Indian ExpressImportant
NHAI Asks Police to Guard Barrier-Free Toll Booths to Stop Unpaid Travel
Reported by Harshdeep Singh (Fact-Checker) · Indian Express - Business ·
